Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoliflodacin Bioequivalence and DDI Study
NCT05635305Phase 1Completed
- Sponsor
- GARDP
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zoliflodacin in gonorrhea (2 arms), sponsored by GARDP. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 4 more. Started Nov 2022; status: completed.
02
Drugs
zoliflodacin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT05635305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635305.